Outcome differences by sex in oncology clinical trials
Abstract Identifying sex differences in outcomes and toxicity between males and females in oncology clinical trials is important and has also been mandated by National Institutes of Health policies. Here we analyze the Trialtrove database, finding that, strikingly, only 472/89,221 oncology clinical...
Saved in:
Main Authors: | Ashwin V. Kammula, Alejandro A. Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-024-46945-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relevance of tumor boards for the inclusion of patients in oncological clinical trials
by: Hendrik Dapper, et al.
Published: (2023-03-01) -
Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
by: Razelle Kurzrock, et al.
Published: (2022-09-01) -
Correction: Relevance of tumor boards for the inclusion of patients in oncological clinical trials
by: Hendrik Dapper, et al.
Published: (2025-01-01) -
Abeloff's Clinical Oncology /
by: Niederhuber, John E.
Published: (2014) -
Next-generation ctDNA-driven clinical trials in precision immuno-oncology
by: Charu Aggarwal, et al.
Published: (2023-01-01)